NASDAQ:MNLO - Menlo Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.29 +0.29 (+3.63 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$8.04
Today's Range$7.97 - $8.29
52-Week Range$6.99 - $39.86
Volume2,269 shs
Average Volume72,118 shs
Market Capitalization$196.69 million
P/E Ratio-1.41
Dividend YieldN/A
Menlo Therapeutics logoMenlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio18.85
Quick Ratio18.85


Trailing P/E Ratio-1.41
Forward P/E Ratio-2.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.58 million
Price / Sales41.59
Cash FlowN/A
Price / CashN/A
Book Value($2.60) per share
Price / Book-3.19


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares22,980,000

Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc (NASDAQ:MNLO) posted its earnings results on Wednesday, May, 9th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The company earned $0.50 million during the quarter, compared to analyst estimates of $0.56 million. View Menlo Therapeutics' Earnings History.

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Menlo Therapeutics.

What price target have analysts set for MNLO?

4 equities research analysts have issued 1-year target prices for Menlo Therapeutics' shares. Their predictions range from $11.00 to $48.00. On average, they anticipate Menlo Therapeutics' share price to reach $36.00 in the next twelve months. View Analyst Ratings for Menlo Therapeutics.

Who are some of Menlo Therapeutics' key competitors?

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the folowing people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 52)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 46)
  • Dr. Paul S. Kwon M.D., Chief Medical Officer
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 53)
  • Dr. Xiaoming Zhang Ph.D., Sr. VP of Non-Clinical & Pharmaceutical Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and JMP Securities was co-manager.

When does the company's lock-up period expire?

Menlo Therapeutics' lock-up period expires on Tuesday, July 24th. Menlo Therapeutics had issued 7,000,000 shares in its IPO on January 25th. The total size of the offering was $119,000,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Has Menlo Therapeutics been receiving favorable news coverage?

Press coverage about MNLO stock has trended positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Menlo Therapeutics earned a coverage optimism score of 0.33 on Accern's scale. They also assigned news headlines about the company an impact score of 46.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Menlo Therapeutics' major shareholders?

Menlo Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.99%), VHCP Management II LLC (1.48%), Rock Springs Capital Management LP (1.44%), Franklin Resources Inc. (0.87%), JPMorgan Chase & Co. (0.50%) and Nexthera Capital LP (0.32%). View Institutional Ownership Trends for Menlo Therapeutics.

Which major investors are buying Menlo Therapeutics stock?

MNLO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., VHCP Management II LLC, Rock Springs Capital Management LP, Franklin Resources Inc., JPMorgan Chase & Co., Nexthera Capital LP, Northern Trust Corp and Landscape Capital Management L.L.C.. View Insider Buying and Selling for Menlo Therapeutics.

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $8.29.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $196.69 million and generates $4.58 million in revenue each year. The company earns $-29,070,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Menlo Therapeutics employs 32 workers across the globe.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected]

MarketBeat Community Rating for Menlo Therapeutics (MNLO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  16 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  37
MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.